These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Contemporary approach to essential thrombocythemia and polycythemia vera. Aruch D, Mascarenhas J. Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193 [Abstract] [Full Text] [Related]
3. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Sever M, Newberry KJ, Verstovsek S. Leuk Lymphoma; 2014 Dec; 55(12):2685-90. PubMed ID: 24524340 [Abstract] [Full Text] [Related]
5. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Tefferi A. Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582 [Abstract] [Full Text] [Related]
6. A clinical update in polycythemia vera and essential thrombocythemia. Tefferi A, Solberg LA, Silverstein MN. Am J Med; 2000 Aug 01; 109(2):141-9. PubMed ID: 10967156 [Abstract] [Full Text] [Related]
7. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Tefferi A, Barbui T. Am J Hematol; 2019 Jan 01; 94(1):133-143. PubMed ID: 30281843 [Abstract] [Full Text] [Related]
8. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Barbui T, Finazzi G. Semin Thromb Hemost; 2007 Jun 01; 33(4):321-9. PubMed ID: 17525889 [Abstract] [Full Text] [Related]
13. Front-line therapy in polycythemia vera and essential thrombocythemia. Barbui T, Finazzi MC, Finazzi G. Blood Rev; 2012 Sep 01; 26(5):205-11. PubMed ID: 22784966 [Abstract] [Full Text] [Related]
14. Target hematologic values in the management of essential thrombocythemia and polycythemia vera. Hernández-Boluda JC, Gómez M. Eur J Haematol; 2015 Jan 01; 94(1):4-11. PubMed ID: 24814134 [Abstract] [Full Text] [Related]
15. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HA, van Vliet HH. Platelets; 2006 Dec 01; 17(8):528-44. PubMed ID: 17127481 [Abstract] [Full Text] [Related]
16. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Lim Y, Lee JO, Kim SH, Kim JW, Kim YJ, Lee KW, Lee JS, Bang SM. Thromb Res; 2015 May 01; 135(5):846-51. PubMed ID: 25743883 [Abstract] [Full Text] [Related]
18. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations]. Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L. Vnitr Lek; 2011 Feb 01; 57(2):189-213. PubMed ID: 21416861 [Abstract] [Full Text] [Related]